SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
Expands institutional footprint with potential penetration of more than ~ 60% of the U.S. market, while expanding reach across EMS providers and ...
MarketWatch
SCIENTURE Broadens Commercial Access for REZENOPY(TM), Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
The MarketWatch News Department was not involved in the creation of this content. Expands institutional footprint with potential penetration of more than 60% of the U.S. market, while expanding reach ...